Orion Pharma Presents ODM-212 Trial Data

Orion announced the first clinical data from its Phase 1/2 TEADES trial for ODM-212, an investigational oral pan-TEAD inhibitor, at the 2026 American Society of Clinical Oncology Annual Meeting. The results indicated that ODM-212 was well tolerated, with proteinuria as the most common treatment-related adverse event. Importantly, ODM-212 demonstrated early efficacy in patients with advanced solid tumors, particularly in mesothelioma and epithelioid hemangioendothelioma (EHE), which are characterized by Hippo pathway dysregulation. Professor Outi Vaarala, Executive Vice President of Research & Development at Orion, highlighted the encouraging safety profile and clinical activity, supporting continued development of ODM-212 as both a monotherapy and in combination with other treatments. The ongoing clinical program includes the TEADES and TEADCO trials, exploring ODM-212 across multiple solid tumors.